In response to intervention, though anti-PD-1 alone was not able to reduce tumor burden, combination of anti-PD-1 treatment with depletion of tumor-derived PGRN led to a dramatic decrease of tumor burden (Fig. 7A, B) and a higher apoptosis rate (Fig. 7F). Here, PDCD1 is linked to neoplasm.